Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

Read more. ResMed CPAP masks subject to Class I recall over magnetic interference issue Six reported injuries related to magnets on the headgear of CPAP machines by ResMed Ltd. have resulted in a ...

ResMed is a leading manufacturer of Continuous Positive Airway Pressure (CPAP) devices ... which is at the moment the gold standard, is a mask that keeps the airway open. It does not require ...

Top Deals on ResMed CPAP Machines and Masks As an official distributor of ResMed products, Air Voel is offering exceptional deals on their top-rated CPAP machines and masks. ResMed's innovative ...

Much like the headgear that keeps the CPAP mask in place, a chinstrap may gradually weaken and ... two integrated filters that can be replaced with this same frequency. The ResMed AirSense machines ...

Without heated tubing, a heated humidifier may also cause condensation to form in the tubing and lead to sleep disruption due to noise or water splashing into the mask. If you have decided you don’t ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...